<DOC>
	<DOCNO>NCT01906632</DOCNO>
	<brief_summary>To investigate gene expression profile immunological associate analysis relate immunotherapy response patient malignant tumor DC-CIK immunotherapy .</brief_summary>
	<brief_title>Gene Expression Profiling Malignant Tumor Predict Therapeutic Response DC-CIK Immunotherapy</brief_title>
	<detailed_description>1 . The patient malignant tumor treat dendritic cell ( DC ) plus cytokine induce killer cell ( CIK ) . 2 . Venous blood ( 4 ml ) collect subject place tube contain Ethylene Diamine Tetraacetic Acid ( EDTA ) treatment . Lymphocytes sorted Fluorescence Activated Cell Sorting ( FACS ) store -80°C processing . 3 . The T-Cell Receptor/B-Cell Receptor gene expression detect micro-array。 4 . Estimate Immunotherapy response , time disease progression , survival rate clinical benefit response patient . Response assess use Response Evaluation Criteria Solid Tumor Group ( RECIST ) guideline . Degree response use divide cancer two group : sensitive non-sensitive immunotherapy . 5 . Compare gene expression profile different immunotherapy response group explore mechanism predict DC-CIK immunotherapy response .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histologically confirm malignant tumor ; Age : 1880 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; At least one measurable lesion accord RECIST criterion ; Adequate bone marrow , cardiac , liver , renal function ; Life expectancy ≥2 month ; Not receive antitumor treatment Informed consent sign previous history malignancy ; Uncontrolled central nervous system metastasis ; Serious uncontrolled concurrent medical illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>